Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Department Of Defense was posted on May 28, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

FUROSEMIDE INJECTIO

Closed
SPE2DP-26-T-3579Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The contract is for the procurement of Furosemide Injection, USP, a sterile, preservative-free, latex-free, and non-DEHP pharmaceutical product labeled for intravenous and intramuscular use, with each milliliter containing 10 mg of active ingredient in a 2 mL single-dose vial. Units are packaged in quantities of 25 vials per unit, with a total shelf life of 24 months and a minimum requirement of 21 months of remaining shelf life upon receipt by the first government activity. Product must be stored at controlled room temperature (20°C to 25°C), with permitted excursions between 15°C and 30°C, protected from light, and only used if the solution remains clear and colorless. The product is regulated by the FDA and must be labeled and marked in strict compliance with Medical Marking Standard No. 1, superseding MIL-STD-129, and all packaging and palletization must adhere to DLA Packaging Requirements for Procurement (RP001). The contract mandates that mercury or mercury-containing compounds are prohibited unless specifically exempted, such as in functional batteries, instruments, or sensors, with additional containment requirements per SPE2DP-26-T-3579 Section B. Delivery is required FOB destination within five days of award to USS HOPPER DDG 70 at FPO AP 96667, with shipping to be accomplished via the fastest traceable means and parcel post explicitly forbidden. All units must be commercially packaged in sealed containers suitable for safe transport, with hazardous material handling governed by FED-STD-313 and either TQ requirement IP025 or ASTM D3951, subject to the overriding authority of the DLA Master List of Technical and Quality Requirements. The solicitation is issued under SPE2DP-26-T-3579 as a simplified acquisition with a response deadline of June 3, 2026, and the NAICS code 325412 applies. The contract incorporates a suite of FAR and DFARS clauses including requirements related to whistleblower rights, cybersecurity, supply chain integrity, human trafficking, equal opportunity, sustainable products, and hazardous material identification, all under deviation 2026-00038 that modifies several standard clauses. Compliance with the Buy American Act and Berry Amendment is mandatory, and the offeror must maintain current representations in the System for Award

General Info

Procurement of Furosemide Injection, 25 vials/package, 10 mg/mL, 24-month shelf life, DoD delivery.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSAView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

UNIT 100182 BOX 1, FPO, AP, 96667, USA

Set-Aside

NONE

Documents

(1)

RFQ SPE2DP-26-T-3579 Medical Supply Chain Pharma FSA

PDFrfq

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
View Agency Profile
Office AddressUSA

Full Description

Show more
FUROSEMIDE INJECTIO
FUROSEMIDE INJECTION,USP
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
.
RX ONLY, LATEX-FREE, NON-DEHP,
PRESERVATIVE-FREE
.
FOR INTRAVENOUS AND INTRAMUSCULAR INJECTION
.
EACH ML CONTAINS: FUROSEMIDE USP 10 MG
.
VIAL VOLUME: 2 ML
.
UNIT OF ISSUE IS A PACKAGE CONTAINING
25 SINGLE DOSE VIALS
.
TOTAL SHELF LIFE IS 24 MONTHS.
.
THERE SHALL BE A MINIMUM OF 21 MONTHS
OF REMAINING SHELF LIFE AT THE TIME OF
RECIPT BY THE FIRST GOVERNMENT ACTIVITY.
.
STORE AT CONTROLLED ROOM TEMPERATURE
20° TO 25°C (68° TO 77°F).
.
EXCURSIONS PERMITTED TO 15° TO 30°C (59° TO 86°F)
(SEE USP CONTROLLED ROOM TEMPERATURE).
.
USE ONLY IF THE SOLUTION IS CLEAR AND COLORLESS
DO NOT USE IF SOLUTION IS DISCOLORED.
.
PROTECT FROM LIGHT.
.
LABELING AND MARKING MUST IN ACCORDANCE WITH
MEDICAL MARKING STANDARD NO. 1A DATED 4 FEBRUARY 2013
.
5/20/2015
MERCURY OR MERCURY CONTAINING COMPOUNDS SHALL
NOT BE INTENTIONALLY ADDED TO<(>,<)> OR COME IN DIRECT
CONTACT WITH<(>,<)> ANY HARDWARE OR SUPPLIES FURNISHED
UNDER THIS CONTRACT. EXCEPTION: FUNCTIONAL MERCURY
USED IN BATTERIES, FLUORESCENT LIGHTS, REQUIRED
INSTRUMENTS; SENSORS OR CONTROLS; WEAPON SYSTEMS;
AND CHEMICAL ANALYSIS REAGENTS SPECIFIED BY NAVSEA.
PORTABLE FLUORESCENT LAMPS AND PORTABLE INSTRUMENTS
CONTAINING MERCURY SHALL BE SHOCK PROOF AND CONTAIN
SPE2DP-26-T-3579
SECTION B
A SECOND BOUNDARY OF CONTAINMENT OF THE MERCURY OR
MERCURY COMPOUND. (IAW NAVSEA 5100-003D).
.
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description.
APPLICABLE TO ALL MEDICAL ACQUISITIONS:
PACKAGING AND PACKING SHALL BE COMMERCIAL AS SPECIFIED IN THE PROCUREMENT DOCUMENT.
EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED IN A SUITABLE SEALED UNIT CONTAINER CAPABLE OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR BREAKAGE.
UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT THE LOWEST RATE, TO POINT OF DELIVERY CALLED FOR IN THE CONTRACT OR ORDER.
MATERIAL MUST BE MARKED IAW MEDICAL MARKING STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES TO MIL-STD-129.
COPIES OF MEDICAL MARKING STANDARD NO. 1 (MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
RS016: Shelf-life requirement RS001 for a TYPE I (CODE M) item with a shelf life of 24 months (non-extendable) applies to this item.
FRESENIUS KABI, LLC 57KZ6 P/N 28002 FRESENIUS KABI, LLC 57KZ6 P/N NDC63323-0280-02 HOSPIRA WORLDWIDE LLC 72QE3 P/N NDC00409-6102-02
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7016946406 0001 PG 1.000
NSN/MATERIAL:6505011575117
DELIVERY (IN DAYS):0005
DELIVER FOB: DESTINATION
SPE2DP-26-T-3579
SECTION B
PR: 7016946406 PRLI: 0001 CONT’D
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA-QUP:001
IF MATERIAL IS CONSIDERED HAZARDOUS IAW FED-STD-313,
PACKAGE IN ACCORDANCE WITH TQ REQUIREMENT IP025.
IF THE MATERIAL IS NOT CONSIDERED HAZARDOUS, IN ACCORDANCE WITH
FED-STD-313, THE MATERIAL SHALL BE COMMERCIALLY PACKAGED IN ACCORDANCE
WITH ASTM D3951.
All DLA Master List of Technical and Quality Requirements take precedence over ASTM D3951. Mark and label all packaging and packing in accordance with MIL-STD-129. The Unit of Issue (U/I) and Quantity per Unit Pack (QUP) will be as specified in the contract/purchase order. PALLETIZATION SHALL BE IN ACCORDANCE WITH RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
PARCEL POST ADDRESS:
R21944
USS HOPPER DDG 70
UNIT 100182 BOX 1
FPO AP 96667
US
VESSEL SHIPMENT. TRANSPORTATION SEE DLAD PROC NOTE C19. FIRST DESTINATION TRANSPORTATION SEE DLAD PROC
NOTE C20 AND CONTRACT
FREIGHT SHIPPING ADDRESS:
R21944
USS HOPPER DDG 70
DLA VENDORS: USE VSM FOR
US
RDD 999/NMCS SHIPMENT. SHIP BY FASTEST TRACEABLE MEANS. DO NOT USE PARCEL POST.
M/F: (TCN) R219445241HM32
RDD: 999
PROJ: E5K TP 1
SUPP ADD: YNHM01 SIG: A
FOR GOVERNMENT USE ONLY: (IPD) 03
DIC: A4A DIST: 9B ADV: 2A FC: N7
Need Ship Date:00/00/0000 Original Required Delivery Date:09/09/2025
SPE2DP-26-T-3579 NSN/Part Number: 6505-01-157-5117 Quantity: 1 PG Purchase Request: 7016946406QTY: 1 Delivery: 5 days ADO

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS